Before Stelios Tzellos built a single market forecast, he spent years studying a virus. His doctoral research at Imperial College London examined Epstein-Barr virus gene regulation, specifically the molecular basis for why type 1 EBV transforms cells more efficiently than type 2. It is the kind of question that sits far from any spreadsheet or commercial strategy. And yet the way of thinking it required turned out to be directly applicable to the work he does now in oncology analytics.
Stelios Tzellos of the UK is a professional working in business insights, analytics, and oncology marketing at AstraZeneca, with earlier roles at GlobalData and IQVIA. The path from virology to pharmaceutical forecasting is not a common one. But the habits of mind that laboratory research builds are the same habits that separate a useful market model from a misleading one.
A Virus Does Not Behave Predictably
Epstein-Barr virus is a study in variability. It infects most of the human population, usually without consequence, yet it is linked to several cancers. The same virus, in different cellular contexts, produces wildly different outcomes. Studying why type 1 EBV transforms cells more readily than type 2 means accepting that biological systems do not follow simple rules. The same input can produce different results depending on conditions that are not always visible.
That lesson transfers directly to oncology markets. A drug that works in one patient subgroup fails in another. A therapy that dominates in one line of treatment barely registers in the next. An analyst trained to expect uniformity will keep being surprised. An analyst trained on biological variability builds models that anticipate it.
Reading a System Instead of a Number
Laboratory research teaches you to think in systems. A gene does not act alone. It interacts with other genes, with regulatory signals, with the environment of the cell. Understanding any single behaviour means understanding the network it sits inside.
Tzellos brings that systems view to oncology forecasting. A market is not a single number to be calculated. It is a system of interacting parts: the disease, the patients, the diagnostics, the competing therapies, the prescribing habits, and the access rules. Change one part and the others respond.
The Discipline of Distinguishing Signal From Noise
Bench science is largely the practice of telling real effects from artifacts. An experiment produces a result, and the researcher’s job is to determine whether that result means something or whether it is noise, contamination, or chance. Get this wrong and you build years of work on a false foundation.
This discipline is exactly what pharmaceutical data demands. Real-world datasets are full of patterns that look meaningful but are not. A spike in prescriptions might reflect a genuine shift or a quirk in how one health system records its data. Tzellos applies the same scrutiny he learned at the bench, asking what a pattern can actually support before building a forecast on it.
From the Bench to the Portfolio
The connection between virology and market strategy is not obvious, which is part of why so few people make it. Most molecular biology graduates move into medical writing, regulatory work, or drug discovery. Moving into market analytics meant carrying the scientific mindset into a place that did not expect it.
At AstraZeneca, Tzellos leads cross-functional projects that support product strategy and portfolio decisions. The scientific training shows up not as a list of facts but as a way of approaching problems: expect variability, think in systems, separate signal from noise, and never trust a clean number that has not been questioned.
A virus taught him that biology is complicated and that simple answers are usually wrong. Cancer markets are complicated for the same reason.